ENvue Medical, Inc. (NAOV) Financier

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Tyler, Texas and currently employs 15 full-time employees. The company went IPO on 2015-04-24. The firm focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.